Maralixibat Chloride
FDA-approved product (solution, oral), marketed as Livmarli.
- Registered studies
- 5
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Alagille syndrome
- Pruritus
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other drugs for bile therapy
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
5registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Maralixibat Chloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more51.4% AI-predicted activityagainst E. coli50+ registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma51.2% AI-predicted activityagainst E. coli48 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more51.1% AI-predicted activityagainst E. coli50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.0% AI-predicted activityagainst E. coli50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma50.9% AI-predicted activityagainst E. coli46 registered studies
- DasatinibExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more50.8% AI-predicted activityagainst E. coli50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more50.5% AI-predicted activityagainst E. coli35 registered studies
- IvosidenibExisting use: Acute myeloid leukemia, Cholangiocarcinoma50.4% AI-predicted activityagainst E. coli50+ registered studies
- Thiamine HydrochlorideExisting use: Anemia (phenotype), Chronic kidney disease, Encephalopathy and 2 more50.4% AI-predicted activityagainst E. coli50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.4% AI-predicted activityagainst E. coli16 registered studies
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma50.3% AI-predicted activityagainst E. coli3 registered studies
- Ziprasidone MesylateExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 5 more50.3% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
NCT05543174 · start 2023-01-16
Registered record
- Registry ID
- NCT05543174
- Conditions
- Alagille Syndrome (ALGS)
- Interventions
- TAK-625
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2023-01-16
- Completion
- 2025-07-25
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlagille Syndrome (ALGS)InterventionTAK-625PhasePhase 3Registry statusCompletedA Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT05543187 · start 2023-01-10
Registered record
- Registry ID
- NCT05543187
- Conditions
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Interventions
- TAK-625
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2023-01-10
- Completion
- 2025-07-22
- Enrolment
- 5
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProgressive Familial Intrahepatic Cholestasis (PFIC)InterventionTAK-625PhasePhase 3Registry statusCompletedA Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
NCT04729751 · start 2021-09-09
Registered record
- Registry ID
- NCT04729751
- Conditions
- Progressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver Disease
- Interventions
- Maralixibat
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-09-09
- Completion
- 2024-12-17
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProgressive Familial Intrahepatic Cholestasis; Alagille Syndrome; Cholestatic Liver DiseaseInterventionMaralixibatPhasePhase 2Registry statusCompletedMRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
NCT04168385 · start 2020-01-16
Registered record
- Registry ID
- NCT04168385
- Conditions
- Cholestatic Liver Disease
- Interventions
- Maralixibat
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2020-01-16
- Completion
- 2024-09-04
- Enrolment
- 52
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCholestatic Liver DiseaseInterventionMaralixibatPhasePhase 2Registry statusCompletedSafety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
NCT02160782 · start 2014-10-28
Registered record
- Registry ID
- NCT02160782
- Conditions
- Alagille Syndrome
- Interventions
- LUM001 (Maralixibat); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-10-28
- Completion
- 2020-05-28
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAlagille SyndromeInterventionLUM001 (Maralixibat); PlaceboPhasePhase 2Registry statusCompleted